Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 03, 2026 08:00 ET | Source: Prolium Bioscience, Inc.

Prolium Bioscience Launches with $50 Million and Announces First Patients Dosed with PRO-203, a Potential Best-in-Class CD20xCD3 T-Cell Engager, for Severe Autoimmune Disease

Initial $50M Series A investment from founding investor RTW Investments Proceeds will fund clinical development of PRO-203 in systemic sclerosis (SSc) and multiple additional severe autoimmune...